Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade

Circulation

Volumn 97, Issue 8, 1998, Pages 752-756

  Verhaar, Marianne C ^b   Strachan, Fiona E ^a   Newby, David E ^a   Cruden, Nicholas L ^a   Koomans, Hein A ^c   Rabelink, Ton J ^c   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NONE

Author keywords

Endothelin; Flow; Nitric oxide; Prostaglandins; Receptors

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE SYNTHASE; PROSTANOID;

ADULT; ARTICLE; BLOOD VESSEL TONE; BRACHIAL ARTERY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

EID: 0032478272     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.8.752     Document Type: Article

References (40)

1. Arai H, Hori S. Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-732.
2. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T, Cloning of a cDNA encoding a non-isopeptide-selcctive subtype of the endothelin receptor. Nature. 1990;348:732-735.
3. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
4. Haynes WG, Ferro CJ, OKane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860-1870.
5. A receptor. Life Sci. 1992;50:247-255.
6. De Nucci G, Thomas R. D'Orleans Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988;85:9797-9800.
7. Tsukahara H, Ende H. Magazine HI, Bahou WF, Goligorsky MS. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells: receptor coupling to nitric oxide synthase J Biol Chem. 1994;269:21778-21785.
8. B receptors in human vascular smooth muscle. J Cardiovasc Pharmacol. 1993;22(suppl 8):S22-S25.
9. B receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992;186:867-873.
10. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
11. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 1995;92:357-363.
12. A receptors in humans? Trends Pharmacol Sci. 1994;15:9-11.
13. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-590.
14. Lüscher TF Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, Siebenmann R, Turina M, Buhler FR. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res. 1990;66:1088-1094.
15. Warner TD, Schmidt HH, Murad F. Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin 3. Am J Physiol 1992;262:H1600-H1605.
16. Redmond EM, Cahill PA, Hodges R, Zhang S, SitzmanJV. Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells. J Cell Physiol. 1996;166:469-479.
17. Thompson A. Valeri CR, Lieberthal W. Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in rats. Am J Physiol. 1995;269:H743-H748.
18. G-monomethyl-L-arginine in conscious rats. Br J Plarmacol. 1996:118:352-354.
19. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
20. Battistini B, Chailler P, D'Orleans Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Piptides. 1993;14:385-399.
21. Ferro CJ, Webb DJ. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs. 1996;51:12-27.
22. Warner TD, Elliott JD, Ohlstein EH. California dreamin' 'bout endothelin: emerging new therapeutics. Trends Pharmacol Sci. 1996;17:177-181.
23. Ferro CJ, Haynes WG, Hand MF, Webb DJ. The vascular endothelin and nitric oxide systems in essential hypertension. J Hypertens. 1996;14(suppl 1):S50. Abstract.
24. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M, Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A. 1994;91:4892-4896.
25. B-mediated vunoconstriction by BQ-788 in human veins in vivo. Br J Clin Pharmacol. In press. Abstract.
26. Stroes ES, Lüscher TF, de Groot FG, Koomans HA, Rabelink TJ. Cyclosporin A increases nitric oxide activity in vivo. Hypertension. 1997;29:570-575.
27. Stroes ES, Koomam HA, de Bruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467-471.
28. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone. Lancet. 1989;2:997-999.
29. Calver A. Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulindependent diabetes. J Clin Invest. 1992;90:2548-2554.
30. Heavey DJ, Barrow SE, Hickling NE, Ritter J. Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man. Nature. 1985;318:186-188.
31. Webb DJ. The pharmacology of human blood vessels in vivo.J Vasc Res. 1995;32:2-15.
32. Chang PC, Verlinde R, Bruning T, van Brummelen P. A microcomputerbased, R-wave triggered system for hemodynamic measurements in the forearm. Comput Biol Med. 1988;18:157-163.
33. Wiinberg N, Walter-Larson S, Eriksen C, Nielsen PE. An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure. J Ambulatory Mouit. 1988;1:303-309.
34. Ikegawa R, Malsumura, Tsukahara Y, Takaoka M, Morimoto S. Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big endothelin-1 in cultured vascular endothelial cells and smooth muscle cells. FEBS Lett. 1991;293:45-48.
35. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-tenninal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol. 1996;119:311-314.
36. Dagassan PH, Breu V, Clozel M, Vogt P, Turina M, Kiowski W, Clozel JP. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 1996;27:147-153.
37. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996;94:2131-2137.
38. Cannun CR, Burnett JC Jr, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation. 1996,93:646-651.
39. Love MP, Ferro CJ, Haynes WG, Webb DJ, Mc.Murray JJ. Selective or nonselective endothelin receptor blockade in chronic heart failure? Circulation. 1996;94(suppl I):I-2899-I-2900. Abstract.
40. Collier JG, Lorge RE, Robinson BF. Comparison of the efrects of tolmesoxide (RX71107), diazoxide, hydralazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol. 1978;5:35-44.